Diseased upper motor neurons are preserved in mouse study
Northwestern Medicine scientists have discovered two ways to preserve diseased upper motor neurons that would normally be destroyed in ALS, based on a study in mice published in Nature Gene Therapy. Upper motor neurons initiate movement, and they degenerate in ALS.
These neurons have a pathology — called TDP-43 pathology — in which aggregating proteins inside the cell become misfolded and toxic to the neuron. This happens in about 90 percent of all ALS patient brains and is one of the most common problems in neurodegeneration, detected also in the brains of frontotemporal dementia and Alzheimer’s disease patients.
When there is TDP-43 pathology, this activates astrocytes and microglia — two types of cells that once were supportive, but now become deleterious — to attack and destroy the diseased neurons in the brain.
“When astrocytes and microglia eat diseased motor neurons, they are gone for good, and the window of opportunity to improve their health is lost,” said lead investigator Hande Ozdinler, PhD, associate professor in the Ken and Ruth Davee Department of Neurology. “There is no turning back from neurodegeneration when the neurons are destroyed by astrocytes and microglia.”
“That is a major problem in ALS and in other neurodegenerative diseases, and one of the reasons the disease progresses quickly. Normally, that fast progression correlates with the activation of the astrocytes and microglia. We need to find ways to keep them calm,” Ozdinler said.
In two new studies, Ozdinler and colleagues identify two independent ways to reduce the destruction of the upper motor neurons that are diseased with TDP-43 pathology in ALS by calming the astrocytes and microglia. They found that a gene therapy approach and a small molecule treatment are both effective in mouse models of TDP-43 pathology. The genetic delivery of hepatocyte growth factor (HGF) soothes the astrocytes in the brain.
The Northwestern scientists also found that when the integrity of the mitochondria (the energy producer for the cell) is improved inside the diseased neurons, the astrocytes stop attacking them. Scientists fed the TDP-43 mouse models of ALS with the compound SBT-272, which binds and repairs the inner mitochondrial membrane. This prevents it from breaking down or becoming leaky, a phenomenon that is broadly observed in diseased neurons in ALS and other neurodegenerative diseases.
“We started giving the SBT-272 to mice when they began to show symptoms of ALS, meaning when the mitochondria were already defective,” Ozdinler said. “The compound helped repair the mitochondrial damage, reducing the impact of TDP-43 pathology. Most importantly, astrocytes and microglia stopped attacking. This is then reflected on neuronal heath.”
This finding about improving mitochondrial health was recently published in Neurobiology of Disease.
The next steps in the research are to develop combination treatments to overcome complex diseases like ALS. “We believe a combination of treatments would work much better and would bring us much closer to a cure, as we need to do two things at the same time: (1) improve the health of diseased upper motor neurons; and (2) decrease the deleterious effects of the astrocytes and microglia that kill them,” Ozdinler said.
Other Northwestern authors on the studies are Mukesh Gautam, PhD, research assistant professor of Neurology; Barıs Genç, PhD; Benjamin Helmold; Angela Ahrens; Öge Gözütok, DVM; and Suchitra Swaminathan, PhD, research assistant professor of Medicine in the Division of Rheumatology.
The research was funded in part by grant R21-NS085750 from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health, NUCATS Translational Innovation Grant, Spastic Paraplegia Foundation, Stealth BioTherapeutics and Helixmith, Co., Ltd.
